GenomeQuest and Questel Partner on IP Platform Integration

GenomeQuest and Questel Partner on IP Platform Integration

DENVER--(BUSINESS WIRE)--PIUG 2012 Annual Conference – Questel, a leader in online information services for over 40 years, and GenomeQuest, a global provider of large-scale genomic software applications, announced today a partnership to integrate the two companies' platforms for researching and managing global IP. Specifically, GQ-IP users will now have the option to review biological sequence patents directly on Questel's Orbit platform.

GQ-IP is the world's only complete, integrated research platform for global IP on biological sequences. It offers researchers the tools needed to complete assignments in sequence patentability, freedom to operate, potential infringement, competitive intelligence and business opportunity. Known for one of the largest IP databases collections in the world, Orbit offers a wide array of tools for searching, mapping, watching, archiving and sharing information, as well as analyzing and managing IP portfolios.

"We have invested heavily in content quality and coverage," said Questel CEO Charles Besson. "Our translations, concept extraction, assignee normalization and abstract enhancements are being continuously reprocessed and optimized to improve the speed and precision of search results. GenomeQuest users will love this new universe."

The integration makes it easy for researchers to take advantage of GenomeQuest's unique collection and dedicated biological sequence search engine as well as Questel's unmatched coverage of value-added patent databases, semantic search and advanced patent landscaping tools.

"GenomeQuest has built up GQ-IP's ease of use and depth of content to allow users to complete more research and more reporting in less time," said Richard Resnick, CEO of GenomeQuest. "Our partnership with Questel further extends our interactive research environment and expands the high level of productivity that GQ-IP provides to customers. We look forward to collaborating with Questel on additional integration opportunities in the coming months."

Questel and GenomeQuest are welcoming their partner customers with a free trial period. More information on this offer, including upcoming educational webinars, is available at Welcome Questel and Welcome GenomeQuest.

About Questel:

Questel has been focusing on its core business, Intellectual Property since its inception in the early 70's. We provide a suite of leading-edge patent, trademark and industrial design services to researchers, lawyers, scientists, and competitive intelligence professionals. Questel built Fampat, the largest databases collections in the world and available in our portal Orbit.com for searching, mapping, watching, archiving and sharing information, as well as analyzing and managing IP portfolios. Since 2007, Questel has been supported by the leading European mid-cap Private Equity investor, Syntegra Capital. For more information, please visit www.questel.com.

About GenomeQuest:

GenomeQuest is a global provider and consistent pioneer in large-scale genomic software applications. Based on a whole/multi-genome engine and hosting platform, the company's products now include GQ-IP for global research and management of intellectual property on genomic sequences, GQ-Dx for decision-support and research in molecular diagnostics, and GQ-Ag for agricultural research. GenomeQuest serves major pharmaceutical companies, global agriculture firms, biotech firms, IP legal teams, genome centers, academic research centers, diagnostic labs, and universities around the world. Learn more at www.genomequest.com.

Contacts

Waggener Edstrom Worldwide
Chris Stamm or Will Hall, 617-234-4118
[email protected]

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.